HansBiomed Statistics
Total Valuation
HansBiomed has a market cap or net worth of KRW 91.82 billion. The enterprise value is 122.69 billion.
Market Cap | 91.82B |
Enterprise Value | 122.69B |
Important Dates
The next estimated earnings date is Thursday, May 15, 2025.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
HansBiomed has 12.99 million shares outstanding. The number of shares has increased by 12.32% in one year.
Current Share Class | n/a |
Shares Outstanding | 12.99M |
Shares Change (YoY) | +12.32% |
Shares Change (QoQ) | +0.29% |
Owned by Insiders (%) | 26.25% |
Owned by Institutions (%) | 0.77% |
Float | 7.13M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.14 |
PB Ratio | 1.43 |
P/TBV Ratio | 1.44 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 127.80, with an EV/FCF ratio of -39.23.
EV / Earnings | -15.26 |
EV / Sales | 1.52 |
EV / EBITDA | 127.80 |
EV / EBIT | n/a |
EV / FCF | -39.23 |
Financial Position
The company has a current ratio of 0.99, with a Debt / Equity ratio of 0.57.
Current Ratio | 0.99 |
Quick Ratio | 0.35 |
Debt / Equity | 0.57 |
Debt / EBITDA | 7.82 |
Debt / FCF | -11.64 |
Interest Coverage | -0.41 |
Financial Efficiency
Return on equity (ROE) is -12.70% and return on invested capital (ROIC) is -0.45%.
Return on Equity (ROE) | -12.70% |
Return on Assets (ROA) | -0.38% |
Return on Invested Capital (ROIC) | -0.45% |
Return on Capital Employed (ROCE) | -1.07% |
Revenue Per Employee | 309.02M |
Profits Per Employee | -30.81M |
Employee Count | 261 |
Asset Turnover | 0.67 |
Inventory Turnover | 1.05 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.44% in the last 52 weeks. The beta is 0.66, so HansBiomed's price volatility has been lower than the market average.
Beta (5Y) | 0.66 |
52-Week Price Change | -50.44% |
50-Day Moving Average | 7,947.00 |
200-Day Moving Average | 9,356.25 |
Relative Strength Index (RSI) | 35.51 |
Average Volume (20 Days) | 12,366 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HansBiomed had revenue of KRW 80.65 billion and -8.04 billion in losses. Loss per share was -620.75.
Revenue | 80.65B |
Gross Profit | 50.54B |
Operating Income | -735.76M |
Pretax Income | -6.56B |
Net Income | -8.04B |
EBITDA | 4.65B |
EBIT | -735.76M |
Loss Per Share | -620.75 |
Balance Sheet
The company has 5.54 billion in cash and 36.40 billion in debt, giving a net cash position of -30.86 billion or -2,376.18 per share.
Cash & Cash Equivalents | 5.54B |
Total Debt | 36.40B |
Net Cash | -30.86B |
Net Cash Per Share | -2,376.18 |
Equity (Book Value) | 64.29B |
Book Value Per Share | 4,949.73 |
Working Capital | -675.08M |
Cash Flow
In the last 12 months, operating cash flow was -496.44 million and capital expenditures -2.63 billion, giving a free cash flow of -3.13 billion.
Operating Cash Flow | -496.44M |
Capital Expenditures | -2.63B |
Free Cash Flow | -3.13B |
FCF Per Share | -240.83 |
Margins
Gross margin is 62.67%, with operating and profit margins of -0.91% and -9.97%.
Gross Margin | 62.67% |
Operating Margin | -0.91% |
Pretax Margin | -8.13% |
Profit Margin | -9.97% |
EBITDA Margin | 5.77% |
EBIT Margin | -0.91% |
FCF Margin | n/a |
Dividends & Yields
HansBiomed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -12.32% |
Shareholder Yield | -12.32% |
Earnings Yield | -8.76% |
FCF Yield | -3.41% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
HansBiomed has an Altman Z-Score of 2.07. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.07 |
Piotroski F-Score | n/a |